- The World Economic Forum (WEF) annual meeting was held earlier this year in Davos, Switzerland. This platform is used by world leaders, business moguls, and economists to meet and discuss the pressing issues facing the world.
In an interview with Business Insider, Robin Carhart-Harris, head of psychedelic research at Imperial College in London, stated that “the climate’s looking good” for classifying psychedelics into approved medical treatments.
The interview took place at the Wednesday session called “The New Science of Psychedelics,” was led by Carhart-Harris to deliberate on the “untapped potential of psychedelic drugs” according to WEF’s official website.
The debate surrounding the ability and potential of psychedelics like MDMA, marijuana, and LSD to treat medical disorders and illnesses has been trending for a while. Though there is some evidence that psilocybin, the active ingredient in psychedelic mushrooms, has the ability to help people struggling with anxiety, depression, and even alcoholism, the true effects, and subsequent side effects are still being studied actively.
A number of for-profit companies have been attempting to get ahead in the race of selling it as a medical treatment while others refer to their psilocybin experiences in countries like the Netherlands where it is already legal. They contend that substances like psilocybin should be reclassified from a Schedule 1 drug with no known medical benefits to a Schedule IV one with conventional prescription drugs by the Food and Drug Administration in the U.S.
The FDA has already approved a small number of trials involving psilocybin, but the medical science backing it is still in its early stages.
With a strong enough push from the private for-profit sector even the Silicon Valley, psychedelics might end up following the footsteps of medical marijuana.